PTC Therapeutics (PTCT) financial statements
PTC Therapeutics reported revenue of $1.7B in fiscal 2025, up 40.2% a year over 9 years.
Net income was $683M and the operating margin 50.1%, against -159.7% in 2016.
Free cash flow was $702M.
The diluted share count rose 159% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from PTC Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83M | $194M | $265M | $307M | $381M | $539M | $699M | $938M | $807M | $1.7B |
| Cost of revenue | $0 | $5M | $13M | $12M | — | — | — | — | — | — |
| Gross profit | $83M | $190M | $252M | $295M | — | — | — | — | — | — |
| Research and development | $118M | $117M | $172M | $257M | $478M | $541M | $651M | $667M | $534M | $455M |
| Selling, general and admin | $97M | $121M | $154M | $203M | $245M | $286M | $326M | $333M | $301M | $347M |
| Operating income | -$132M | -$64M | -$116M | -$241M | -$432M | -$374M | -$447M | -$440M | -$303M | $867M |
| Pre-tax income | -$142M | -$78M | -$128M | -$240M | -$403M | -$518M | -$587M | -$696M | -$363M | $697M |
| Income tax | $569,000 | $1M | -$29,000 | $12M | $35M | $6M | -$28M | -$70M | $176,000 | $14M |
| Net income | -$142M | -$79M | -$128M | -$252M | -$438M | -$524M | -$559M | -$627M | -$363M | $683M |
| EPS (diluted) | -$4.17 | -$2.02 | -$2.75 | -$4.27 | -$6.64 | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
| Diluted shares | 34M | 39M | 47M | 59M | 66M | 70M | 72M | 75M | 77M | 88M |
| Gross margin | 100.0% | 97.6% | 95.2% | 96.0% | — | — | — | — | — | — |
| Operating margin | -159.7% | -33.1% | -43.7% | -78.6% | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% |
| Net margin | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
Balance sheet
Fiscal years, from PTC Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $232M | $191M | $228M | $687M | $1.1B | $773M | $411M | $877M | $1.1B | $1.9B |
| Receivables | $25M | $40M | $68M | $56M | $70M | $110M | $156M | $161M | $159M | $182M |
| Inventory | $0 | $11M | $16M | $19M | $19M | $16M | $22M | $31M | $23M | $80M |
| Total current assets | $261M | $249M | $321M | $779M | $1.2B | $954M | $694M | $1.2B | $1.4B | $2.3B |
| Property, plant and equipment | $7M | $8M | $13M | $22M | $34M | $53M | $73M | $87M | $61M | $55M |
| Goodwill | — | $0 | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M |
| Total assets | $269M | $392M | $1.1B | $1.6B | $2.2B | $1.9B | $1.7B | $1.9B | $1.7B | $2.9B |
| Total current liabilities | $50M | $82M | $167M | $236M | $277M | $509M | $406M | $603M | $581M | $968M |
| Long-term debt | $98M | $145M | $141M | $294M | $309M | $282M | $572M | $284M | $285M | — |
| Total liabilities | $150M | $235M | $768M | $1.0B | $1.7B | $1.9B | $2.1B | $2.7B | $2.8B | $3.1B |
| Shareholders' equity | $120M | $156M | $351M | $594M | $482M | $1M | -$347M | -$819M | -$1.1B | -$205M |
| Net debt | $40M | $33M | -$16M | $26M | $100M | $242M | $292M | -$310M | -$494M | -$698M |
Cash flow
Fiscal years, from PTC Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$104M | -$10M | -$28M | -$99M | -$194M | -$251M | -$357M | -$158M | -$108M | $711M |
| Capital spending | $2M | $3M | $7M | $14M | $18M | $28M | $32M | $28M | $7M | $9M |
| Free cash flow | -$105M | -$13M | -$35M | -$112M | -$212M | -$280M | -$389M | -$187M | -$114M | $702M |
| Stock-based compensation | $35M | $31M | $33M | $42M | $70M | $104M | $110M | $102M | $75M | $75M |
| Net borrowing | $0 | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | -127.4% | -6.8% | -13.1% | -36.6% | -55.7% | -51.9% | -55.6% | -19.9% | -14.2% | 40.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PTCT.
Open PTCT in InvestinglyQuestions
What was PTC Therapeutics's revenue in 2025?
$1.7B in fiscal 2025, from its 10-K filing.
How much free cash flow does PTC Therapeutics generate?
$702M in fiscal 2025 (operating cash flow minus capital spending).
From PTC Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.